Agape ATP Corporation (NASDAQ:ATPC) shares surged 43.89% to $0.13 in after-hours trading on Tuesday.Check out the current price of ATPC stock here.According to Benzinga Pro data, the stock of the Malaysia-based investment holding company closed at $0.090, down 25.86%.Company Statement On VolatilityAgape ATP issued a statement about recent volatility in its common stock, saying management is not aware of any material, undisclosed corporate developments or adverse operating conditions that would explain the r ...

Core Viewpoint - Agape ATP Corporation (ATPC) addresses recent stock price volatility, confirming stable business operations and no known adverse conditions affecting performance [1][2]. Company Operations - The company continues to operate normally and is not aware of any undisclosed corporate developments that could explain stock price fluctuations [1]. - ATPC is committed to transparency and will communicate material developments through timely disclosures and regulatory filings [2]. Business Focus - ATPC is focused on diversifying its business in health and wellness products and sustainable green energy to enhance sustainable equity performance for investors [2]. - The company specializes in health and wellness products and energy-saving solutions, aiming to improve quality of life and promote sustainable development [3].

Core Insights - After-hours trading in the U.S. saw significant gains in small-cap and micro-cap biotech stocks, driven by a mix of catalyst-driven moves and sentiment-based rebounds following the Fed's rate cut Group 1: Notable After-Hours Gainers - Agape ATP Corp. (ATPC) surged 29.41% after hours to $0.088, despite no specific news, reflecting a broader risk-on sentiment in micro-cap stocks [1] - Corbus Pharmaceuticals Holdings, Inc. (CRBP) rose 12.76% after hours to $11.57, driven by anticipation of a key clinical update on its Phase 1a study of CRB-913 [2] - Anebulo Pharmaceuticals, Inc. (ANEB) increased 8.37% after hours to $2.33, aligning with the overall positive sentiment in small-cap biotech [3] - Cue Biopharma, Inc. (CUE) gained 13.12% after hours to $0.54, with no new developments, indicating a macro-driven recovery in biotech [4] - Curis, Inc. (CRIS) saw a 7.68% increase after hours to $1.3999, following positive clinical data presented at the ASH Annual Meeting [5] - Skye Bioscience, Inc. (SKYE) rose 7.02% after hours to $1.22, benefiting from the overall biotech market lift [6] - Cerus Corporation (CERS) increased 3.17% after hours to $1.95, continuing its upward trend after announcing a purchasing agreement with Blood Centers of America [7]

Core Insights - The market has experienced significant price movements among several companies, with notable declines in stock values, indicating a critical reassessment of their market positions [1][7] Company Summaries - WORK Medical Technology Group Ltd. (NASDAQ:WOK) saw a dramatic stock price decrease of 96.00% to $0.22, despite its subsidiary securing a $114,000 service contract, with trading volume reaching 75,256,805 [2][8] - Agape ATP Corporation (NASDAQ:ATPC) experienced a 95.09% drop in stock price to $0.06, even with a strategic partnership involving a purchase order for EN590 diesel and Jet Fuel A1, and a trading volume of 81,386,239 [3][8] - POMDOCTOR Ltd. (NASDAQ:POM) reported an 89.11% decline in stock price to $0.59, following the release of its unaudited financial results for the first half of fiscal 2025, indicating challenges in balancing expansion and operational discipline [4][8] - ChowChow Cloud International Ho (NYSE American:CHOW) saw an 87.69% decrease in stock price to $1.44 after closing its IPO, raising nearly $12 million, with a significant drop from a year-high of $21.91 [5] - Aimei Health Technology Co., Ltd (Symbol: AFJK) experienced a 62.15% decrease in stock price to $33.5, following a dramatic surge and subsequent decline in after-hours trading, reflecting notable market adjustments [6]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Chijet Motor Company, Inc. (CJET) is up 40% at $2.67 - JX Luxventure Group Inc. (JXG) is up 19% at $4.12 - Inspire Medical Systems, Inc. (INSP) is up 15% at $103.50 - Epsium Enterprise Limited (EPSM) is up 15% at $4.14 - Oscar Health, Inc. (OSCR) is up 12% at $15.13 - Green Dot Corporation (GDOT) is up 11% at $13.21 - Butterfly Network, Inc. (BFLY) is up 6% at $2.82 - Cullinan Therapeutics, Inc. (CGEM) is up 5% at $10.00 - Vir Biotechnology, Inc. (VIR) is up 5% at $5.99 - Nvni Group Limited (NVNI) is up 5% at $3.17 [3] Premarket Losers - Clearside Biomedical, Inc. (CLSD) is down 69% at $0.82 - Twin Hospitality Group Inc. (TWNP) is down 20% at $2.84 - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is down 15% at $1.35 - Mobile-Network Solutions (MNDR) is down 12% at $4.16 - Waldencast plc (WALD) is down 10% at $2.75 - authID Inc. (AUID) is down 9% at $1.21 - EZGO Technologies Ltd. (EZGO) is down 6% at $1.98 - SciSparc Ltd. (SPRC) is down 5% at $2.34 - Twin Vee Powercats Co. (VEEE) is down 5% at $1.70 - Agape ATP Corporation (ATPC) is down 5% at $1.22 [4]

Revenue Performance - Revenue for Q3 2025 was $370,593, an increase of $39,304 or approximately 11.9% compared to $331,289 in Q3 2024[240][241] - Revenue from the network marketing business decreased by $11,947, or approximately 41.0%, while revenue from skin care and healthcare products increased by $72,160 or approximately 392.1%[241][242] - For the nine months ended September 30, 2025, total revenue was $1,125,129, an increase of $162,158 or approximately 16.8% compared to $962,971 in the same period of 2024[255][256] - Revenue from skin care and healthcare products for the nine months ended September 30, 2025 increased by $136,285 or approximately 740.5%[256] Profitability and Loss - Gross profit for Q3 2025 was $239,103, representing a gross margin of approximately 64.5%, up from $184,185 and a gross margin of 55.6% in Q3 2024[246] - Net loss for Q3 2025 increased to $595,370 from a net loss of $524,039 in Q3 2024, an increase of $71,331[254] - Net loss increased from $1,659,449 for the nine months ended September 30, 2024, to $1,931,535 for the same period in 2025, an increase of $272,086[268] Operating Expenses - Total operating expenses for Q3 2025 were $840,424, an increase of $108,129 or approximately 14.8% from $732,295 in Q3 2024[247] - Cost of revenue for the nine months ended September 30, 2025 was $520,800, an increase of $138,995 or approximately 36.4% from $381,805 in 2024[258] - General and administrative expenses for the nine months ended September 30, 2025 amounted to $2,324,451, an increase of $171,562 or approximately 8.0% from $2,152,889 in 2024[264] - Commission expenses for the nine months ended September 30, 2025 increased by $27,777 or approximately 117.8% to $51,350 compared to $23,573 in 2024[263] Cash Flow and Working Capital - Net cash used in operating activities for the nine months ended September 30, 2025, was $2,205,074, compared to $2,080,879 for the same period in 2024[270] - Net cash used in investing activities for the nine months ended September 30, 2025, was $23,000,667, primarily from advances for investment[273] - Net cash provided by financing activities for the nine months ended September 30, 2025, was $23,297,009, consisting of proceeds from the issuance of common stock for $23,000,000[274] - Working capital as of September 30, 2025, was $22,585,047, compared to $1,656,571 as of December 31, 2024[269] Accounting Standards and Regulations - The FASB issued ASU 2023-09 requiring companies to disclose specific categories in the rate reconciliation if the effect is equal to or greater than 5% of the amount computed by multiplying pretax income by the applicable statutory income tax rate, effective after December 15, 2024[303] - The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements[303] - The FASB issued ASU 2024-01 clarifying the scope application of profits interest and similar awards, effective for annual reporting periods beginning after December 15, 2024[300] - The adoption of ASU 2024-01 has no material impact on the Company's consolidated financial statements[300] - The FASB issued ASU 2024-02 to remove extraneous references in accounting guidance, effective for annual reporting periods beginning after December 15, 2024, with no significant impact expected[301] - The Company has reviewed all recently issued accounting standards updates and is evaluating their applicability and impact[302] - The FASB issued ASU 2024-03 requiring additional disclosures about the nature of expenses in the income statement, effective after December 15, 2026[304] - The Company is currently evaluating the effect of adopting ASU 2024-03[304] Credit Risk and Allowance - The Company believes that its concentration of credit risk in trade receivables is mitigated by an ongoing credit evaluation process and short collection terms[311] - The Company does not generally require collateral from customers and evaluates the need for an allowance for credit loss based on specific customer credit risk factors[311] - The allowance for credit loss was recognized at $6,559 as of September 30, 2025, down from $32,857 as of December 31, 2024[284] Assets and Liabilities - The carrying amounts of operating right-of-use assets and property, plant, and equipment were $119,021 and $15,122, respectively, as of September 30, 2025[281] - Accumulated deficits increased to $11,420,899 as of September 30, 2025, from $9,518,045 as of December 31, 2024[269] - The company has no significant off-balance sheet arrangements that could materially affect its financial condition as of September 30, 2025[277]

Financial Performance - For the three months ended June 30, 2025, the company generated revenue of $465,499, an increase of $152,460 or approximately 48.7% compared to $313,039 for the same period in 2024[231] - Revenue from the company's network marketing business decreased by $13,097, or approximately 44.8%, while new revenue streams included $55,446 from wellness and wellbeing lifestyle and $135,434 from green energy[231] - For the six months ended June 30, 2025, total revenue was $754,536, an increase of $122,854 or approximately 19.4% compared to $631,682 in 2024[246] Cost and Expenses - Cost of revenue for the three months ended June 30, 2025 amounted to $256,559, an increase of $137,081 or approximately 114.7% from $119,478 in 2024[233] - Total operating expenses for the three months ended June 30, 2025 were $845,901, an increase of $198,755 or approximately 30.7% from $647,146 in 2024[237] - Cost of revenue for the six months ended June 30, 2025 was $389,310, an increase of $154,609 or approximately 65.9% from $234,701 in 2024[248] Profitability - Gross profit for the three months ended June 30, 2025 was $208,940, with a gross margin of approximately 44.9%, down from $193,561 and 61.8% in 2024[236] - Gross profit for the six months ended June 30, 2025 was $365,226, with a gross margin of approximately 48.4%, down from $396,981 and 62.8% in 2024[250] - The company recorded a net loss of $623,246 for the three months ended June 30, 2025, an increase of $190,931 from a net loss of $432,315 in 2024[245] - Net loss increased to $1,336,165 for the six months ended June 30, 2025, compared to a net loss of $1,135,410 for the same period in 2024, representing an increase of $200,755[258] Cash Flow - Net cash used in operating activities for the six months ended June 30, 2025, was $1,948,332, compared to $1,656,000 for the same period in 2024, indicating a higher cash outflow[260] - Net cash used in investing activities surged to $23,000,660 for the six months ended June 30, 2025, compared to only $3,567 in 2024, primarily due to advances for investment[263] - Net cash provided by financing activities was $23,115,678 for the six months ended June 30, 2025, mainly from the issuance of common stock for $23,000,000[265] Financial Position - Working capital as of June 30, 2025, was $23,149,202, a significant increase from $1,656,571 as of December 31, 2024[259] - The company had accumulated deficits of $10,834,072 as of June 30, 2025, compared to $9,518,045 as of December 31, 2024[259] - The allowance for credit loss increased to $42,838 as of June 30, 2025, from $32,857 as of December 31, 2024[276] Tax and Accounting Standards - The provision for income taxes was $0 for the six months ended June 30, 2025, compared to $16,678 for the same period in 2024[257] - The FASB issued ASU 2023-09 requiring companies to disclose specific categories in the rate reconciliation if the effect of reconciling items is equal to or greater than 5% of the amount computed by multiplying pretax income by the applicable statutory income tax rate[296] - The adoption of ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, with no material impact on the consolidated financial statements[291] - The Company is currently evaluating the impact of ASU 2024-01 on its consolidated financial statements, which clarifies the scope application of profits interest and similar awards[292] - The amendments in ASU 2024-02 are effective for annual reporting periods beginning after December 15, 2024, and are not expected to result in significant accounting changes[293] - The FASB issued ASU 2024-03 requiring additional disclosures about the nature of expenses included in the income statement, effective for annual periods beginning after December 15, 2026[297] - The Company is evaluating the effect of adopting ASU 2024-04 regarding the accounting for induced conversions of convertible debt instruments, effective after December 15, 2025[298] - The Company has reviewed all recently issued accounting standards updates and considers their applicability and impact[295] - There are no new accounting standards that will have a material impact on the consolidated financial position or cash flows, except for those mentioned[294] Risk Management - The Company believes that its concentration of credit risk in trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms[303] - The Company does not currently hedge exposures denominated in foreign currencies, limiting its direct foreign exchange risk[302] - The company recorded no inventory write-downs for the six months ended June 30, 2025, but had an inventory write-off of $6,897[271] - The company had no significant off-balance sheet arrangements as of June 30, 2025, that could materially affect its financial condition[268]

Revenue Performance - For the three months ended March 31, 2025, the company generated revenue of $289,037, a decrease of approximately 9.3% compared to $318,643 for the same period in 2024[234]. - Revenue from the company's network marketing business decreased by $10,532 or approximately 28.4%, while revenue from complementary health therapies decreased by $29,318 or approximately 10.4%[234]. Cost and Profitability - Cost of revenue increased by $17,528 or approximately 15.2%, amounting to $132,751 for the three months ended March 31, 2025[236]. - Gross profit for the three months ended March 31, 2025 was $156,286, representing a gross margin of 54.1%, down from 63.8% in the same period of 2024[239]. - Selling expenses increased by $12,704 or approximately 25.2%, totaling $63,052 for the three months ended March 31, 2025[241]. - Net loss increased by $9,825, resulting in a net loss of $712,919 for the three months ended March 31, 2025, compared to a net loss of $703,094 for the same period in 2024[247]. Cash Flow and Working Capital - As of March 31, 2025, the company had working capital of $23,775,576, significantly up from $1,656,571 as of December 31, 2024[248]. - Net cash used in operating activities for the three months ended March 31, 2025 was $1,453,874, compared to $1,243,460 for the same period in 2024[249]. - Net cash used in investing activities for the three months ended March 31, 2025 was $23,000,649, primarily from advances for investment[252]. - Net cash provided by financing activities for the three months ended March 31, 2025 was $22,994,658, compared to a net cash used of $899 in the same period of 2024[255]. Asset Management - As of March 31, 2025, the allowance for credit loss was recognized at $41,360, an increase from $32,857 as of December 31, 2024, reflecting a growth of approximately 25.3%[264]. - The carrying amounts of operating right-of-use assets were $189,059 as of March 31, 2025, down from $224,595 as of December 31, 2024, indicating a decrease of about 15.8%[261]. - The Company recorded inventory write-offs of $6,777 for the three months ended March 31, 2025, compared to $0 for the same period in 2024[259]. - The Company has not recognized any impairment losses on operating right-of-use assets and property, plant, and equipment as of March 31, 2025[261]. Revenue Recognition and Accounting Policies - The Company’s revenue recognition follows the five-step model under ASC Topic 606, ensuring that revenue reflects the transfer of goods and services to customers[268]. - The Company’s sales of skin care, health, and wellness products are recognized when control is transferred to the customer, with a return period of 60 days[271]. - The Company evaluates the need for an allowance for credit loss based on ongoing credit evaluations and current economic conditions[291]. - The Company has not hedged exposures denominated in foreign currencies, limiting direct foreign exchange risk[290]. - The adoption of ASU 2023-07 regarding segment reporting is expected to have no material impact on the consolidated financial statements[280]. Equity and Financing - The Company issued Representative's Warrants to purchase up to 115,500 shares at $4.4 per share, effective from October 13, 2023[266].

Revenue Performance - Total revenue for the year ended December 31, 2024 decreased by $108,341, or approximately 7.6%, compared to 2023, with network marketing revenue dropping by $259,072, or approximately 65.4%[158] - Revenue from the provision of complementary health therapies increased by $87,622, or approximately 8.5%, during the same period[159] - The company launched new revenue streams in wellness and wellbeing lifestyle and green energy, contributing $64,854 in revenue[159] Cost and Expenses - Cost of revenue for 2024 amounted to $563,599, representing approximately 42.6% of revenue, an increase of $69,083, or approximately 14.0% from 2023[161] - Gross profit for 2024 was $759,148, with a gross margin of approximately 57.4%, down from $936,572 and 65.4% in 2023[163] - Selling expenses for 2024 significantly decreased by $466,291, or approximately 74.1%, totaling $162,712 compared to $629,003 in 2023[166] - General and administrative expenses increased by $768,858, or approximately 32.4%, totaling $3,134,874 in 2024 due to higher executive salaries and Nasdaq listing fees[168] Net Loss and Cash Flow - Net loss for the year ended December 31, 2024 was $2,486,044, an increase of $376,109, or approximately 17.8%, compared to the previous year[171] - Working capital as of December 31, 2024 was $1,656,571, a decrease from $4,113,614 in 2023[172] - Net cash used in operating activities for 2024 was $2,726,215, compared to $2,001,823 in 2023[173] - Net cash used in financing activities for the year ended December 31, 2024 was $11,856, primarily for the reduction of finance lease liability[177] - Net cash provided by financing activities for the year ended December 31, 2023 was $5,398,037, consisting of proceeds from issuance of common stock of $5,501,520, cash used for shares repurchased of $93,889, and reduction of finance lease liability of $9,594[177] Inventory and Credit Management - The company recognized an inventory write-down of $7,081 for the year ended December 31, 2024, compared to $0 for 2023[181] - The allowance for expected credit loss increased to $32,857 for the year ended December 31, 2024, from $542 in 2023[185] - Credit risk is primarily associated with accounts receivable, which the company mitigates through ongoing credit evaluations and short collection terms[214] - The company does not generally require collateral from customers, relying instead on credit evaluations[214] - The need for an allowance for doubtful accounts is evaluated based on specific customer credit risk, historical trends, and other relevant information[214] Accounting and Financial Reporting - The company adopted ASU 2014-09 for revenue recognition, which requires identifying performance obligations and recognizing revenue when control of goods and services transfers to customers[188] - The company derives revenues from sales contracts recognized when control of skin care, health, and wellness products is transferred to customers[191] - The company provides products and services for sustainability and energy savings, recognizing revenue based on the percentage of cost incurred[198] - The adoption of recent accounting standards has no material impact on the consolidated financial statements for the year ended December 31, 2024[211] Foreign Currency and Risk Management - The majority of the company's revenues are denominated in Malaysian Ringgit, while expenses are in Malaysian Ringgit, U.S. Dollar, and Hong Kong Dollar[212] - The company does not currently hedge exposures denominated in foreign currencies or use derivative financial instruments[212] - The value of the company's Common Stock may be affected by the foreign exchange rates between U.S. Dollar and Malaysian Ringgit, and U.S. Dollar and Hong Kong Dollar[213]

Revenue Performance - Revenue for the three months ended September 30, 2024, was $331,289, a decrease of $24,025 or approximately 6.8% compared to $355,314 for the same period in 2023[208]. - Revenue from the Company's network marketing business decreased significantly by $60,075, or approximately 67.3%, while revenue from complementary health therapies increased by $17,646, or approximately 6.6%[208]. - For the nine months ended September 30, 2024, total revenue was $962,971, a decrease of $77,046 or approximately 7.4% from $1,040,017 in 2023[218]. - Revenue from the Company's network marketing business for the nine months ended September 30, 2024, decreased by $223,271, or approximately 70.1%[218]. Cost and Expenses - Cost of revenue for the three months ended September 30, 2024, amounted to $147,104, an increase of $26,518 or approximately 22.0% from $120,586 in 2023[209]. - Total operating expenses for the three months ended September 30, 2024, were $732,295, an increase of $180,489 or approximately 32.7% from $551,806 in 2023[211]. - General and administrative expenses for the nine months ended September 30, 2024, amounted to $2,152,889, an increase of $598,647 or approximately 38.5% from $1,554,242 in 2023[224]. Profitability and Loss - Gross profit for the three months ended September 30, 2024, was $184,185, representing a gross margin of approximately 55.6%, down from 66.1% in 2023[210]. - Net loss increased to $524,039 for the three months ended September 30, 2024, compared to a net loss of $324,735 in 2023, an increase of $199,304[217]. - The net loss for the nine months ended September 30, 2024, increased to $1,659,449 from a net loss of $1,138,259 for the same period in 2023, reflecting an increase of $521,189[228]. Cash Flow and Working Capital - Net cash used in operating activities for the nine months ended September 30, 2024, was $2,080,879, compared to $995,706 for the same period in 2023, indicating an increase of 109.1%[230][231]. - Net cash used in investing activities for the nine months ended September 30, 2024, was $48,611, significantly higher than $7,200 for the same period in 2023[232]. - As of September 30, 2024, the company had working capital of $2,452,343, a decrease from $4,113,614 as of December 31, 2023[228]. Other Income and Tax - Other income for the three months ended September 30, 2024, was $21,196, an increase of $24,910 or approximately 670.7% compared to a net expense of $3,714 in 2023[215]. - For the nine months ended September 30, 2024, the company recorded other income, net of $79,588, representing an increase of approximately 859.7% compared to a net expense of $10,476 for the same period in 2023[225]. - The company recorded a provision for income taxes of $13,803 for the nine months ended September 30, 2024, compared to a tax benefit of $2,712 for the same period in 2023[227]. Financial Position and Assets - As of September 30, 2024, accumulated deficits amounted to $8,709,605, up from $7,047,571 as of December 31, 2023[228]. - The carrying amounts of operating right-of-use assets and property and equipment as of September 30, 2024, were $282,734 and $47,508, respectively, down from $357,301 and $77,858 as of December 31, 2023[238]. Accounting Standards and Risks - The adoption of ASU No. 2023-01 regarding leases is effective for reporting periods beginning after December 15, 2023, but is not expected to have a material impact on the financial statements for the nine months ended September 30, 2024[253]. - ASU 2023-07 on segment reporting will enhance disclosures about significant segment expenses and is effective for annual reporting periods beginning after December 15, 2023[256]. - ASU 2023-09 requires disclosure of reconciling items in income tax disclosures that meet a quantitative threshold of 5% and is effective for annual reporting periods beginning after December 15, 2024[257]. - ASU 2024-01 clarifies the scope of profits interest and similar awards, effective for annual reporting periods beginning after December 15, 2024, with no expected impact on financial statements[258]. - The company does not currently have significant direct foreign exchange risk, as most revenues and expenses are denominated in Malaysian Ringgit[260]. - Credit risk is mitigated by an ongoing credit evaluation process and relatively short collection terms, with no collateral generally required from customers[261]. - The company is evaluating the impact of new accounting standards on its consolidated financial statements[255]. - There are no other new accounting standards expected to have a material impact on the consolidated financial position or cash flows[260]. - The company has not hedged exposures denominated in foreign currencies or other derivative financial instruments[260]. - The company believes the concentration of credit risk in trade receivables is substantially mitigated[261].